Hemostatic parameters were examined in 39 patients who underwent allogeneic bone marrow transplantation (BMT). Twenty-six patients survived and 13 patients died within 6 months after BMT. The main causes of death were acute graft-versus-host disease (GVHD: n=6), veno-occlusive disease (VOD: n=2), and thrombotic microangiopathy (TMA: n=2). Plasma levels of D-dimer and thrombomodulin (TM) were significantly elevated in the non-survivor group. Plasma levels of soluble fibrin (SF) and Fas were significantly elevated in the non-survivor group at 1 to 4 weeks after BMT. Plasma levels of thrombin-antithrombin complex (TAT), D-dimer, and tissue plasminogen activator-plasminogen activator inhibitor-1 complex (tPA-PAI-1 complex) were significantly elevated in patients with complications after BMT. Plasma levels of TAT, D-dimer, and tPA-PAI-1 complex were significantly elevated in patients with GVHD. These results suggest that abnormalities of hemostatic parameters might predict poor outcomes or complications in patients with BMT.
Santos GW, Tutschka PJ, Brookmeyer R, et al.Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med1983;309:1347.
2.
Thomas ED, Clift RA, Fefer A, et al.Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med1986;104:155.
3.
Appelbaum FR, Sullivan KM, Buckner CD, et al.Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol1987;5:1340.
4.
Wingard JR, Piantadosi S, Vogelsang GB, et al.Predictions of death from chronic graft-versus-host disease after bone marrow transplantation. Blood1989;74:1428.
5.
Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand?Blood1994;83:2392.
6.
Shulman HM, Hinterberger W.Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant1992;10:197.
7.
Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood1995;85:3005.
8.
Baglin TP. Veno-occlusive disease of the liver complicating bone mallow transplantation. Bone Marrow Transplant1994;13:1.
9.
McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venoocculusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and pre-disposing factors. Hepatology1984;4:116.
10.
Jones RJ, Lee KS, Beschorner WE, et al.Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation1987;44:778.
11.
Shulman HM, Gown AM, Nugent DJ. Hepatic venoocclusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Hepatol1987;127:549.
12.
McDonald GB, Hinds MS, Fisher LD, et al.Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med1993;118:255.
13.
Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant1994;14:495.
14.
Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS. Bone marrow transplant-associated thrombotic microangiopathy: A case series. Bone Marrow Transplant1995;15:247.
15.
Kalhs P, Brugger S, Schwarzinger I, et al.Microangiopathy following allogenic marrow transplantation. Transplantation1995;60:949.
16.
Holler E, Kolb HJ, Hiller E, et al.Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood1989;73:2018.
17.
Sviland L, Sale GE, Myelson D.Endothelial changes in cutaneous graft-versus-host disease: A comparison between HLA matched and mismatched recipients of bone marrow transplantation. Bone Marrow Transplant1990;5:39.
18.
Park Y-D, Yasui M, Yoshimoto T, et al.Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant1997;19:915.
19.
Lee J-H, Lee K-H, Kim S, et al.Relevance of protein C and S, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogenic bone marrow transplantation: A prospective study. Bone Marrow Transplant1998;22:883.
20.
Tamaki S, Wada H, Ohfuzi K, et al.Hemostatic abnormalitis following bone mallow transplantation. Clin Appl Thromb Hemost2002;8:125.
21.
Kanamori H, Murata A, Sasaki S, et al.Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathy. Bone Marrow Transplant1998;21:705.
22.
Brown SA, Davies SV, Fegan C, et al.Hemostatic and fibrinolytic responses to bone marrow transplantation. Br J Haematol1999;104:468.
23.
Morris JD, Harris RE, Hashmi R, et al.Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant1997;20:871.
24.
Lee WY, Kang MI, Oh ES, et al.The role of cytokines in the changes in bone turnover following bone marrow transplantation. Osteoporos Int2002;13:62.
25.
Kanda Y, Tanaka Y, Shirakawa K, et al.Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant1998;22:751.
26.
Ringdén O, Horoeitz MM, Sondel P, et al.Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?Blood1993;81:1094.
27.
Jones RJ, Lee KS, Beschorner WE, et al.Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation1987;44:778.
28.
Testa S, Manna A, Porcellini A, et al.Increased plasma levels of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant1996;18:383.
29.
Wada H, Mori Y, Shimura M, et al.Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol1998;58:189.
30.
Watanabe R, Wada H, Yamamuro M, et al.Good or poor responses of hemostatic molecular markers in patients with hematopoietic disorders after treatment of disseminated intravascular coagulation. Clin Appl Thromb Hemost2003;9:71.
31.
Kayaba H, Hirokawa M, Watanabe A, et al.Serum marker of graft-versus-host disease after bone marrow transplantation. J Allergy Clin Immunol2000;106:S40.
32.
Kanda Y, Tanaka Y, Shirakawa K, et al.Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-vs-host disease. Bone Marrow Transplant1998;22:751.
33.
Liem LM, van Lopik T, van Nieuwenhuijze AE, van Houwelingen HC, Aarden L, Goulmy E.Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. Blood1998;91:1464.
34.
Watanabe R, Wada H, Miura Y, et al.Plasma levels of total plasminogen activator inhibitor-1 and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost2001;7:229.
35.
Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol1993;11:1729.
36.
Fijnheer R, Frijins CJ, Korteweg J, et al.The origin of P-selectin as a circulating plasma protein. Thromb Haemost1997;77:1081.
37.
Salat C, Holler E, Kolb HJ, Pihusch R, Reinhardt B, Hiller E.Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplant1997;19:909.
38.
Kanamori H, Maruta A, Sasaki S, et al.Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathy. Bone Marrow Transplant1998;21:705.
